Valera Pharmaceuticals’ subsidiary company, Valera Pharmaceuticals Ireland Limited, received marketing authorization from the Danish Medicines Agency for Vantas, its 12-month implant for the palliative treatment of advanced prostate cancer.

Vantas is currently marketed and sold in the United States by Valera. The US Food and Drug Administration approved Vantas for sale and distribution in October 2004.

David S. Tierney, President and CEO of Valera stated, "With today's announced approval of Vantas by the Danish regulatory authority, we can begin seeking approvals in other EU member countries through the mutual recognition procedure as we continue to evaluate options for marketing Vantas in Europe."

Valera Pharmaceuticals is a specialty pharmaceutical company concentrating on the development, acquisition and commercialization of products for the treatment of urological and endocrine conditions, diseases and disorders.